Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Pharmacotherapy ; 43(12): 1297-1306, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37475509

RESUMO

OBJECTIVE: To determine if a novel symptom-based alcohol withdrawal syndrome (AWS) protocol in a US Veterans cohort leads to significant clinical improvements in patient outcomes and safety. BACKGROUND: Prior studies of AWS management, oftentimes using the revised version of the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) index, have demonstrated the effectiveness of symptom-triggered therapy for AWS. The Minnesota Detoxification Scale (MINDS) is an alternative to the CIWA-Ar index but remains unevaluated outside of the intensive care unit (ICU) setting. This study assesses outcomes in AWS management prior to and after the implementation of a novel MINDS-based AWS protocol (SDAWP) utilizing a revised MINDS index (MINDS-rev) in an inpatient medical ward setting. METHODS: Retrospective cohort study including encounters prior to (n = 342) and after (n = 338) the implementation of the protocol. Pre- and post-protocol encounters were selected by combinations of diagnostic codes and charting elements. Outcome measures of AWS management were obtained in both groups. The primary endpoint was median total benzodiazepine exposure. Secondary outcomes included median length of hospitalization, median duration of benzodiazepine administration, and the incidence of complications. RESULTS: The median total benzodiazepine exposure in the post-SDAWP group was significantly lower than the pre-SDAWP group (21.2 vs. 12.0 mg, p < 0.0001) and for a significantly shorter median duration of time (4.0 vs. 3.0 days, p < 0.0001). There was no significant difference in the median length of stay (4.0 vs. 4.0 days, p = 0.50). The incidence of delirium tremens (21 vs. 7, p = 0.01) and need for transfer to a higher level of care (33 vs. 12, p = 0.002) was significantly lower in the post-SDAWP group. CONCLUSION: The SDAWP has provided significant improvements in AWS management in our institution and may potentially serve as a template for wider use in other inpatient settings.


Assuntos
Delirium por Abstinência Alcoólica , Alcoolismo , Síndrome de Abstinência a Substâncias , Humanos , Síndrome de Abstinência a Substâncias/diagnóstico , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Alcoolismo/complicações , Alcoolismo/tratamento farmacológico , Delirium por Abstinência Alcoólica/diagnóstico , Delirium por Abstinência Alcoólica/tratamento farmacológico , Estudos Retrospectivos , Pacientes Internados , Minnesota , Benzodiazepinas/efeitos adversos , Etanol
2.
Am J Kidney Dis ; 69(1): 152-155, 2017 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-27692442

RESUMO

As cannabis use has legalized for medical and recreational use in several states, the medical community has become more aware of the drug's potential toxicities. First described in 2004, cannabinoid hyperemesis syndrome is increasingly recognized as a cause of hospitalization among drug users. However, little information is available in the medical literature regarding electrolyte abnormalities in this syndrome. Between 2011 and 2014, six men were treated for cannabinoid hyperemesis syndrome at the Veterans Affairs Medical Center in San Diego, CA, and found to have significant hypophosphatemia (phosphate range, <1-1.3mg/dL). The 6 cases are presented here and possible causes of hypophosphatemia are discussed. In 3 patients, serum phosphate levels normalized spontaneously within hours, suggesting redistribution of phosphate as a potential mechanism. Hyperventilation, which can lead to phosphate redistribution, was observed in 4 of the 6 individuals and may have contributed. Hypophosphatemia is a presenting feature of cannabinoid hyperemesis syndrome in some patients.


Assuntos
Hipofosfatemia/induzido quimicamente , Abuso de Maconha/complicações , Adulto , Idoso , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem
3.
J Am Soc Nephrol ; 19(3): 600-14, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18235090

RESUMO

Chromogranin A is released together with epinephrine and norepinephrine from catecholaminergic cells. Specific endopeptidases cleave chromogranin A into biologically active peptide fragments, including catestatin, which inhibits catecholamine release. Previous studies have suggested that a deficit in this sympathetic "braking" system might be an early event in the pathogenesis of human hypertension. Whether chromogranin A (CHGA) polymorphisms predict end-organ complications of hypertension, such as end-stage renal disease, is unknown. Among blacks, we studied common genetic variants spanning the CHGA locus in 2 independent case-control studies of hypertensive ESRD. Two haplotypes were significantly more frequent among subjects with hypertensive ESRD: 1) in the promoter (5') region, G-462A-->T-415C-->C-89A, haplotype ATC (adjusted odds ratio = 2.65; P = 0.037), and 2) at the 3'-end, C11825T (3'-UTR, C+87T)-->G12602C, haplotype TC (adjusted odds ratio = 2.73, P = 0.0196). Circulating levels of catestatin were lower among those with hypertensive ESRD than controls, an unexpected finding given that peptide levels are usually elevated in ESRD because of reduced renal elimination. We found that the 3'-UTR + 87T variant decreased reporter gene expression, providing a possible mechanistic explanation for diminished catestatin. In summary, common variants in chromogranin A associate with the risk of hypertensive ESRD in blacks.


Assuntos
Negro ou Afro-Americano/genética , Cromogranina A/genética , Hipertensão Renal/genética , Falência Renal Crônica/genética , Regiões 3' não Traduzidas , Cromogranina A/sangue , Epistasia Genética , Feminino , Expressão Gênica , Frequência do Gene , Predisposição Genética para Doença/etnologia , Genótipo , Haplótipos , Humanos , Hipertensão Renal/etnologia , Falência Renal Crônica/etnologia , Desequilíbrio de Ligação , Masculino , Pessoa de Meia-Idade , Razão de Chances , Fragmentos de Peptídeos/sangue , Polimorfismo de Nucleotídeo Único
4.
Ann N Y Acad Sci ; 1148: 282-96, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19120120

RESUMO

Tyrosine hydroxylase (TH) is the rate-limiting enzyme in catecholamine biosynthesis. Does common genetic variation at human TH alter autonomic activity and predispose to cardiovascular disease? We undertook systematic polymorphism discovery at the TH locus, and then tested variants for contributions to sympathetic function and blood pressure. We resequenced 80 ethnically diverse individuals across the TH locus. One hundred seventy-two twin pairs were evaluated for sympathetic traits, including catecholamine production and environmental (cold) stress responses. To evaluate hypertension, we genotyped subjects selected from the most extreme diastolic blood pressure percentiles in the population. Human TH promoter haplotype/reporter plasmids were transfected into chromaffin cells. Forty-nine single nucleotide polymorphisms (SNPs) and one tetranucleotide repeat were discovered, but coding region polymorphism did not account for common phenotypic variation. A block of linkage disequilibrium spanned four common variants in the proximal promoter. Catecholamine secretory traits were significantly heritable, as were stress-induced blood pressure changes. In the TH promoter, significant associations were found for urinary catecholamine excretion, as well as blood pressure response to stress. TH promoter haplotype #2 (TGGG) showed pleiotropy, increasing both norepinephrine excretion and blood pressure during stress. In hypertension, a case-control study (1266 subjects, 53% women) established the effect of C-824T in determination of blood pressure. We conclude that human catecholamine secretory traits are heritable, displaying joint genetic determination (pleiotropy) with autonomic activity and finally with blood pressure in the population. Catecholamine secretion is influenced by genetic variation in the adrenergic pathway encoding catecholamine synthesis, especially at the classically rate-limiting step, TH. The results suggest novel pathophysiological links between a key adrenergic locus, catecholamine metabolism, and blood pressure, and suggest new strategies to approach the mechanism, diagnosis, and treatment of systemic hypertension.


Assuntos
Doenças Cardiovasculares/genética , Predisposição Genética para Doença , Polimorfismo Genético , Estresse Psicológico , Tirosina 3-Mono-Oxigenase/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Sistema Nervoso Autônomo/fisiologia , Pressão Sanguínea/genética , Catecolaminas/genética , Catecolaminas/metabolismo , Feminino , Genótipo , Haplótipos , Humanos , Hipertensão/genética , Hipertensão/fisiopatologia , Desequilíbrio de Ligação , Pessoa de Meia-Idade , Células PC12 , Fenômenos Fisiológicos/genética , Regiões Promotoras Genéticas , Ratos , Gêmeos/genética , Tirosina 3-Mono-Oxigenase/metabolismo , Adulto Jovem
5.
Circulation ; 116(9): 993-1006, 2007 Aug 28.
Artigo em Inglês | MEDLINE | ID: mdl-17698732

RESUMO

BACKGROUND: Tyrosine hydroxylase (TH) is the rate-limiting enzyme in catecholamine biosynthesis. Does common genetic variation at human TH alter autonomic activity and predispose to cardiovascular disease? We undertook systematic polymorphism discovery at the TH locus and then tested variants for contributions to sympathetic function and blood pressure. METHODS AND RESULTS: We resequenced 80 ethnically diverse individuals across the TH locus. One hundred seventy-two twin pairs were evaluated for sympathetic traits, including catecholamine production, reflex control of the circulation, and environmental (cold) stress responses. To evaluate hypertension, we genotyped subjects selected from the most extreme diastolic blood pressure percentiles in the population. Human TH promoter haplotype/reporter plasmids were transfected into chromaffin cells. Forty-nine single-nucleotide polymorphisms were discovered, but coding region polymorphism did not account for common phenotypic variation. A block of linkage disequilibrium spanned 4 common variants in the proximal promoter. Catecholamine secretory traits were significantly heritable (h2), as were stress-induced blood pressure changes. In the TH promoter, significant associations were found for urinary catecholamine excretion and for blood pressure response to stress. TH promoter haplotype 2 (TGGG) showed pleiotropy, increasing both norepinephrine excretion and blood pressure during stress. Coalescent simulations suggest that TH haplotype 2 likely arose approximately 380,000 years ago. In hypertension, 2 independent case-control studies (1266 subjects with 53% women and 927 subjects with 24% women) replicated the effect of C-824T in the determination of blood pressure. CONCLUSIONS: We conclude that human catecholamine secretory traits are heritable, displaying joint genetic determination (pleiotropy) with autonomic activity and finally with blood pressure in the population. Catecholamine secretion is influenced by genetic variation in the adrenergic pathway encoding catecholamine synthesis, especially at the classically rate-limiting step, TH. The results suggest novel pathophysiological links between a key adrenergic locus, catecholamine metabolism, and blood pressure and suggest new strategies to approach the mechanism, diagnosis, and treatment of systemic hypertension.


Assuntos
Sistema Nervoso Autônomo/fisiologia , Pressão Sanguínea , Doenças Cardiovasculares/genética , Catecolaminas/biossíntese , Transcrição Gênica , Tirosina 3-Mono-Oxigenase/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Algoritmos , Doenças Cardiovasculares/epidemiologia , Predisposição Genética para Doença , Variação Genética , Humanos , Cinética , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único , Gêmeos Dizigóticos , Gêmeos Monozigóticos
6.
Diabetes Obes Metab ; 8(6): 621-33, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17026486

RESUMO

Chromogranins or secretogranins (granins), present in secretory granules of virtually all neuroendocrine cells and neurones, are structurally related proteins encoded by different genetic loci: chromogranins A and B, and secretogranins II through VI. Compelling evidence supports both intracellular and extracellular functions for this protein family. Within the cells of origin, a granulogenic or sorting role in the regulated pathway of hormone or neurotransmitter secretion has been documented, especially for chromogranin A (CHGA). Granins also function as pro-hormones, giving rise by proteolytic processing to an array of peptide fragments for which diverse autocrine, paracrine, and endocrine activities have been demonstrated. CHGA measurements yield insight into the pathogenesis of such human diseases as essential hypertension, in which deficiency of the catecholamine release-inhibitory CHGA fragment catestatin may trigger sympathoadrenal overactivity as an aetiologic culprit in the syndrome. The CHGA dysglycaemic fragment pancreastatin is functional in humans in vivo, affecting both carbohydrate (glucose) and lipid (fatty acid) metabolism. Pancreastatin is cleaved from CHGA in hormone storage granules in vivo, and its plasma concentration varies in human disease. The pancreastatin region of CHGA gives rise to three naturally occurring human variants, one of which (Gly297Ser) occurs in the functionally important carboxy-terminus of the peptide, and substantially increases the peptide's potency to inhibit cellular glucose uptake. These observations establish a role for pancreastatin in human intermediary metabolism and disease, and suggest that qualitative hereditary alterations in pancreastatin's primary structure may give rise to interindividual differences in glucose disposition.


Assuntos
Catecolaminas/metabolismo , Síndrome Metabólica/metabolismo , Hormônios Pancreáticos/fisiologia , Vesículas Secretórias/metabolismo , Sequência de Aminoácidos , Animais , Transporte Biológico , Glicemia/metabolismo , Bovinos , Cromogranina A/fisiologia , Diabetes Mellitus Tipo 2/sangue , Humanos , Camundongos , Dados de Sequência Molecular , Hormônios Pancreáticos/genética , Ratos , Alinhamento de Sequência
7.
J Clin Endocrinol Metab ; 90(9): 5414-25, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15956083

RESUMO

RATIONALE: The chromogranin A (CHGA) fragment pancreastatin (human CHGA250-301) impairs glucose metabolism, but the role of human pancreastatin in vivo remains unexplored. METHODS: We studied brachial arterial infusion of pancreastatin (CHGA273-301-amide at approximately 200 nm) on forearm metabolism of glucose, free fatty acids, and amino acids. Plasma pancreastatin was measured in obesity or type 2 diabetes. Systematic discovery of amino acid variation was performed, and the potency of one variant in the active carboxyl terminus (Gly297Ser) was tested. RESULTS: Pancreastatin decreased glucose uptake by approximately 48-50%; the lack of change in forearm plasma flow indicated a metabolic, rather than hemodynamic, mechanism. A control CHGA peptide (catestatin, CHGA352-372) did not affect glucose. Insulin increased glucose uptake, but pancreastatin did not antagonize this action. Pancreastatin increased spillover of free fatty acids by about 4.5- to 6.4-fold, but not spillover of amino acids. Insulin diminished spillover of both free fatty acids and amino acids, but these actions were not reversed by pancreastatin. Plasma pancreastatin was elevated approximately 3.7-fold in diabetes, but was unchanged during weight loss. Proteolytic cleavage sites for pancreastatin in vivo were documented by matrix-assisted laser desorption ionization/time of flight mass spectrometry. Three pancreastatin variants were discovered: Arg253Trp, Ala256Gly, and Gly297Ser. The Gly297Ser variant had unexpectedly increased potency to inhibit glucose uptake. CONCLUSIONS: The dysglycemic peptide pancreastatin is specifically and potently active in humans on multiple facets of intermediary metabolism, although it did not antagonize insulin. Pancreastatin is elevated in diabetes, and the variant Gly297Ser had increased potency to inhibit glucose uptake. The importance of human pancreastatin in vivo as well as its natural variants is established.


Assuntos
Diabetes Mellitus Tipo 2/metabolismo , Glucose/metabolismo , Obesidade/metabolismo , Hormônios Pancreáticos/genética , Hormônios Pancreáticos/metabolismo , Polimorfismo Genético , Sequência de Aminoácidos , Aminoácidos/metabolismo , Sequência de Bases , Estudos de Casos e Controles , Cromogranina A , Diabetes Mellitus Tipo 2/complicações , Ácidos Graxos não Esterificados/metabolismo , Antebraço , Variação Genética , Humanos , Injeções Intra-Articulares , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Obesidade/sangue , Obesidade/complicações , Obesidade/terapia , Hormônios Pancreáticos/administração & dosagem , Hormônios Pancreáticos/farmacologia , Redução de Peso
8.
Clin Pharmacol Ther ; 77(5): 388-403, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15900285

RESUMO

BACKGROUND AND OBJECTIVES: Activation of alpha 2 -adrenergic receptors regulates a broad spectrum of physiologic responses, including blood pressure (centrally and peripherally), sedation, analgesia, insulin release, renal function, cognition, and behavior. The purpose of this study was to explore systematically the local vascular responses in humans triggered by a highly selective alpha 2 -adrenergic agonist (azepexole [B-HT 933]) and whether such responses are dose-dependent or influenced by age, gender, or allelic variation at the drug's receptor. METHODS: We evaluated dorsal hand vein vascular responses to the infusion of a wide spectrum of doses of azepexole, assessing any venodilation, as well as the maximal extent of venoconstriction (B max ) and the dose that produced a half-maximal effect (K d ), in 50 healthy normotensive adults of both genders and 4 ethnicities. Genomic deoxyribonucleic acid from the study subjects was evaluated at polymorphisms of the alpha 2B -adrenergic receptor gene (ADRA2B). RESULTS: We found previously unreported initial venodilation to low doses (10-100 ng/min) of azepexole, followed by progressive, intense venoconstriction to higher doses (200-100,000 ng/min) of the drug. Younger individuals (aged <30 years) had less venodilation than older individuals (aged >30 years) with low doses of azepexole but had a greater extent of venoconstriction at higher doses of azepexole (ANOVA, P = .001). Men had less venodilation than women with low doses of azepexole but greater venoconstriction with higher doses (ANOVA, P = .036). Several common polymorphisms (>10% minor allele frequency) at ADRA2B (insertion/deletion polymorphism [Glu 322-325 ], G-98C, C1182A, and C1776A) did not show an association with either B max or K d for the drug response. The A36G (Thr12Thr) synonymous single nucleotide polymorphism displayed a nonsignificant trend (P = .073) toward higher K d in A/G heterozygotes compared with A/A homozygotes. CONCLUSIONS: Local infusion into the human dorsal hand vein of a highly selective alpha 2 -adrenergic agonist, azepexole, produces biphasic responses, with venodilation at a low dose and intense venoconstriction at a higher concentration. These responses to azepexole show prominent differences as a function of age and gender but appear not to depend on common allelic variations at the ADRA2B receptor.


Assuntos
Agonistas alfa-Adrenérgicos/farmacocinética , Genótipo , Veias/efeitos dos fármacos , Agonistas alfa-Adrenérgicos/administração & dosagem , Adulto , Fatores Etários , Azepinas/administração & dosagem , Azepinas/farmacocinética , Relação Dose-Resposta a Droga , Feminino , Mãos/irrigação sanguínea , Humanos , Infusões Intravenosas , Masculino , Farmacogenética/métodos , Receptores Adrenérgicos alfa 2/efeitos dos fármacos , Receptores Adrenérgicos alfa 2/genética , Fatores Sexuais , Vasoconstrição , Vasodilatação , Veias/patologia , Veias/fisiologia
9.
Hypertension ; 45(2): 294-8, 2005 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15596575

RESUMO

We tested the hypothesis that the presence of a CYP3A5*1 allele is associated with increases in blood pressure in 2 studies of subjects with a total of 683 participants. The first study involving 271 subjects was part of a longitudinal study conducted at Indiana University Medical Center that consisted of 2 phases. The first phase studied the relationship of salt sensitivity with blood pressure, whereas the second phase, conducted approximately 26 years later, studied the relationship between blood pressure, carbohydrate intolerance, and vascular compliance in the same subjects. The second study was a cross-sectional evaluation of 412 normotensive and hypertensive subjects conducted at the University of California San Diego. The second study (Mantel-Haenszel chi(2) test; P=0.05) showed that a greater proportion of black participants with poor blood pressure control had CYP3A5*1/*1 genotype. Evaluation of the untreated blood pressure from phase 1 of the first study showed that the blacks with CYP3A5*3/*3 (146+/-35 mm Hg) had a higher systolic blood pressure than those with the *1/*3 (119+/-14.1 mm Hg; P=0.0006) and *1/*1 (125+/-17.4 mm Hg; P=0.009) genotypes. For blacks in study 2, the CYP3A5*1 allele was more common in hypertensives (Fisher exact test; P=0.025) than normotensives. In whites there was no association between CYP3A5 genotype and blood pressure in either study. We conclude that although untreated blood pressure may be higher in blacks with the CYP3A5*3/*3 genotype, the CYP3A5*1 allele may be associated with hypertension that is more refractory to treatment in this ethnic group.


Assuntos
População Negra/genética , Pressão Sanguínea/genética , Sistema Enzimático do Citocromo P-450/genética , Hipertensão/genética , Alelos , Anti-Hipertensivos/uso terapêutico , Estudos de Casos e Controles , Estudos Transversais , Citocromo P-450 CYP3A , Resistência a Medicamentos , Feminino , Genótipo , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Estudos Longitudinais , Masculino , Sístole , População Branca/genética
10.
Physiol Genomics ; 18(1): 119-27, 2004 Jun 17.
Artigo em Inglês | MEDLINE | ID: mdl-15138309

RESUMO

Chromogranin B (CgB), a major member of the chromogranin/secretogranin family of catecholamine storage vesicle secretory proteins, plays both intracellular (vesiculogenic) and extracellular (prohormone) roles in the neuroendocrine system, and its biosynthesis and release are under the control of efferent sympathetic nerve traffic ("stimulus-transcription coupling"). To explore the role of heredity in control of CgB, we conducted a genome-wide linkage analysis of CgB release in 12 extended CEPH (Centre d'Etude du Polymorphisme Humain) pedigrees. Region-specific radioimmunoassays were used to measure five CgB fragments in plasma: CgB1-16, CgB312-331, CgB439-451, CgB568-577, and CgB647-657. Substantial heritability, as measured by h2r, was observed for three of the fragment concentrations, CgB312-331, CgB439-451, and CgB568-577, which yielded h2r estimates ranging from 0.378 (P = 0.002) to 0.910 (P < 0.0000001). Variance-component genome-wide linkage analysis with 654 microsatellite markers at 5 cM spacing identified a major quantitative trait locus for CgB312-331 on chromosome 11q24-q25 with a maximum multipoint LOD score of 5.84. Significant allelic associations between markers in the region and CgB levels were also observed. Although the 2-LOD confidence interval for linkage did not include the CgB locus itself, known trans-activators of the CgB gene promoter, or prohormone cleaving proteases, examination of positional candidate loci within this region yielded novel and plausible physiological candidates for further exploration. Allelic variation in this region may thus influence effects of sympathetic outflow on target organs in humans.


Assuntos
Cromograninas/biossíntese , Cromossomos Humanos Par 20/genética , Fragmentos de Peptídeos/sangue , Alelos , Animais , Bário/farmacologia , Catecolaminas/metabolismo , Cromogranina B , Cromograninas/sangue , Cromograninas/genética , Cromossomos Humanos Par 11/genética , Estudos de Coortes , Exocitose/efeitos dos fármacos , Variação Genética , Humanos , Escore Lod , Repetições de Microssatélites , Células PC12/efeitos dos fármacos , Células PC12/metabolismo , Pais , Linhagem , Bloqueadores dos Canais de Potássio/farmacologia , Canais de Potássio/efeitos dos fármacos , Canais de Potássio/genética , Estrutura Terciária de Proteína , Locos de Características Quantitativas , Ratos , Irmãos
11.
Am J Hum Genet ; 74(2): 197-207, 2004 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-14740315

RESUMO

The chromogranin/secretogranin proteins are costored and coreleased with catecholamines from secretory vesicles in chromaffin cells and noradrenergic neurons. Chromogranin A (CHGA) regulates catecholamine storage and release through intracellular (vesiculogenic) and extracellular (catecholamine release-inhibitory) mechanisms. CHGA is a candidate gene for autonomic dysfunction syndromes, including intermediate phenotypes that contribute to human hypertension. Here, we show a surprising pattern of CHGA variants that alter the expression and function of this gene, both in vivo and in vitro. Functional variants include both common alleles that quantitatively alter gene expression and rare alleles that qualitatively change the encoded product to alter the signaling potency of CHGA-derived catecholamine release-inhibitory catestatin peptides.


Assuntos
Catecolaminas/fisiologia , Cromograninas/genética , Polimorfismo Genético , Sequência de Aminoácidos , Animais , Sequência de Bases , Cromogranina A , Humanos , Dados de Sequência Molecular , Células PC12 , Filogenia , Ratos , Espectrometria de Massas por Ionização por Electrospray
12.
Curr Opin Nephrol Hypertens ; 12(1): 61-70, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12496668

RESUMO

PURPOSE OF REVIEW: The emerging field of pharmacogenomics has the potential to fundamentally change the management of essential hypertension, a common, perhaps polygenic syndrome characterized by substantial inter-individual variability in drug responsiveness. As understanding of sequence diversity in the human genome progresses, the prospect grows for tailoring the prescription of antihypertensive drugs to complement common genetic variations among individual patients, allowing optimization of blood pressure control and improved avoidance of drug side effects. Some principles of pharmacogenomics are presented here, along with a review of the most recent literature on genetic determinants of antihypertensive drug responses, with a preview of likely developments to come. RECENT FINDINGS: Polymorphisms at candidate pharmacodynamic loci (such as angiotensinogen, angiotensin converting enzyme, and the angiotensin II receptor) have already been shown to predict responses to such specific treatments as angiotensin converting enzyme inhibition and angiotensin II blockade. The National Institutes of Health have established a multi-institutional pharmacogenetics network and knowledge base, whose goals include understanding how common polymorphisms influence therapeutic responses to a variety of drugs, including antihypertensive agents. SUMMARY: The study of genetic determinants of drug responses, particularly at the pharmacodynamic (drug target/receptor and post-receptor) level, is likely to allow us to more precisely tailor therapy to the individual patient, as well as to promote the creation of novel therapies.


Assuntos
Hipertensão/tratamento farmacológico , Hipertensão/genética , Farmacogenética , Animais , Anti-Hipertensivos/farmacocinética , Anti-Hipertensivos/uso terapêutico , Humanos , Polimorfismo Genético/genética , Polimorfismo Genético/fisiologia , Polimorfismo Conformacional de Fita Simples , Sistema Renina-Angiotensina/efeitos dos fármacos , Sistema Renina-Angiotensina/genética
13.
Ann N Y Acad Sci ; 971: 528-9, 2002 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12438174

RESUMO

The physiologic effects of the chromogranin A peptide fragment, pancreastatin, were studied in six healthy Caucasian men, ages 25-46 years. Synthetic pancreastatin (human chromogranin A(273-301)-amide) was infused into the brachial artery of each subject to achieve a local concentration of approximately 200 nM over 15 minutes. Forearm blood flow was measured by strain-gauge plethysmography while (A-V)(glucose) was monitored by arterial and venous sampling. Pancreastatin infusion significantly reduced forearm glucose uptake (mean reduction +/- 1 SEM, 54 +/- 15%; P = 0.028) but did not alter forearm blood flow-indicating a metabolic, rather than hemodynamic, effect. Simultaneous infusion of pancreastatin with insulin (0.1 mU/kg/min) did not diminish insulin-induced forearm glucose uptake, suggesting pancreastatin is not simply a negative insulin modulator. The results of this study suggest that pancreastatin may contribute to the dysglycemia associated with type 2 diabetes and essential hypertension, two common human disease states in which plasma pancreastatin levels are elevated.


Assuntos
Braço/irrigação sanguínea , Hormônios Pancreáticos/química , Hormônios Pancreáticos/fisiologia , Adulto , Velocidade do Fluxo Sanguíneo/efeitos dos fármacos , Glicemia/metabolismo , Cromogranina A , Diabetes Mellitus Tipo 2/fisiopatologia , Glucose/farmacocinética , Hemodinâmica , Humanos , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...